23 July 2024 - Once daily Zorvye foam significantly improved both scalp and body psoriasis in a Phase 2b and a pivotal Phase 3 trial.
Arcutis Biotherapeutics today announced the submission of a supplemental new drug application for Zorvye (roflumilast) foam 0.3%, a once daily, next generation phosphodiesterase-4 inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis.